257 related articles for article (PubMed ID: 18589402)
21. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf W; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Lamb RF; Garner E; Campbell F; Mackey JR; Costello E; Moore MJ; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Halloran CM; Mayerle J; Oláh A; Jackson R; Rawcliffe CL; Scarpa A; Bassi C; Büchler MW;
J Natl Cancer Inst; 2014 Jan; 106(1):djt347. PubMed ID: 24301456
[TBL] [Abstract][Full Text] [Related]
23. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
24. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
Santini D; Schiavon G; Vincenzi B; Cass CE; Vasile E; Manazza AD; Catalano V; Baldi GG; Lai R; Rizzo S; Giacobino A; Chiusa L; Caraglia M; Russo A; Mackey J; Falcone A; Tonini G
Curr Cancer Drug Targets; 2011 Jan; 11(1):123-9. PubMed ID: 20578980
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of human equilibrative nucleoside transporter 1 by RNAi enhances 5-fluorouracil response in pancreatic cancer.
Hu X; Chen W; Xu J
Hepatogastroenterology; 2010; 57(104):1567-72. PubMed ID: 21443122
[TBL] [Abstract][Full Text] [Related]
26. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
27. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
28. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer.
Xi Y; Yuan P; Li T; Zhang M; Liu MF; Li B
Cancer Lett; 2020 Jun; 479():112-122. PubMed ID: 32200037
[TBL] [Abstract][Full Text] [Related]
29. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?
Mohelnikova-Duchonova B; Melichar B
Pancreatology; 2013; 13(6):558-63. PubMed ID: 24280569
[TBL] [Abstract][Full Text] [Related]
30. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.
Oguri T; Achiwa H; Muramatsu H; Ozasa H; Sato S; Shimizu S; Yamazaki H; Eimoto T; Ueda R
Cancer Lett; 2007 Oct; 256(1):112-9. PubMed ID: 17658213
[TBL] [Abstract][Full Text] [Related]
31. Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells.
Molina-Arcas M; Moreno-Bueno G; Cano-Soldado P; Hernández-Vargas H; Casado FJ; Palacios J; Pastor-Anglada M
Biochem Pharmacol; 2006 Dec; 72(12):1646-56. PubMed ID: 16965766
[TBL] [Abstract][Full Text] [Related]
32. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy.
Yamada R; Mizuno S; Uchida K; Yoneda M; Kanayama K; Inoue H; Murata Y; Kuriyama N; Kishiwada M; Usui M; Ii N; Tsuboi J; Tano S; Hamada Y; Tanaka K; Horiki N; Ogura T; Shiraishi T; Takei Y; Katayama N; Isaji S
Pancreas; 2016; 45(5):761-71. PubMed ID: 26784908
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
[TBL] [Abstract][Full Text] [Related]
34. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
[TBL] [Abstract][Full Text] [Related]
35. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Svrcek M; Cros J; Maréchal R; Bachet JB; Fléjou JF; Demetter P
Histopathology; 2015 Feb; 66(3):457-62. PubMed ID: 25298108
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
37. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review.
Nordh S; Ansari D; Andersson R
World J Gastroenterol; 2014 Jul; 20(26):8482-90. PubMed ID: 25024604
[TBL] [Abstract][Full Text] [Related]
38. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
39. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]